FindTrial
Sign In

ALRN-6924

DRUG5 trials

Sponsors

Aileron Therapeutics, Inc., Dana-Farber Cancer Institute

Conditions

Acute Myeloid LeukemiaBrain TumorLeukemiaLymphomaMyelodysplastic SyndromesNon Small Cell Lung CancerPeripheral T-Cell LymphomaPrevention of Chemotherapy-induced Myelosuppression

Phase 1

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
CompletedNCT02264613
Aileron Therapeutics, Inc.Lymphoma, Peripheral T-Cell Lymphoma, Solid Tumor
Start: 2014-10-31End: 2020-04-30Updated: 2026-01-13
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
CompletedNCT02909972
Aileron Therapeutics, Inc.Acute Myeloid Leukemia, Myelodysplastic Syndromes
Start: 2016-09-30End: 2019-08-31Updated: 2019-11-19
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
CompletedNCT03654716
Dana-Farber Cancer InstituteBrain Tumor, Leukemia, Lymphoma +1
Start: 2018-11-01End: 2023-07-17Updated: 2025-02-14
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
TerminatedNCT04022876
Aileron Therapeutics, Inc.Non Small Cell Lung Cancer, Small-cell Lung Cancer
Start: 2019-09-03End: 2022-08-30Updated: 2022-10-10
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
TerminatedNCT05622058
Aileron Therapeutics, Inc.Prevention of Chemotherapy-induced Myelosuppression
Start: 2023-01-09End: 2023-02-22Updated: 2023-02-27

Related Papers

Abstract C064: The investigational peptide drug ALRN-6924, a dual inhibitor of MDMX and MDM2, is an effective myelopreservation agent
Molecular Cancer Therapeutics2019-12-012 citations
Abstract CT112: A Phase I multicenter trial of the dual MDM2/MDMX inhibitor ALRN-6924 in children and young adults with relapsed/refractory pediatric cancers
Cancer Research2019-07-012 citations
PF337 ALRN‐6924, A DUAL INHIBITOR OF MDMX AND MDM2 THAT CAUSES MINIMAL THROMBOCYTOPENIA IN PATIENTS, DISRUPTS DIFFERENT STAGES OF THROMBOPOIESIS COMPARED TO MDM2‐ONLY INHIBITION
HemaSphere2019-06-011 citations
EXCEPTIONAL RESPONSE OF REFRACTORY ATLL WITH MDM4 AMPLIFICATION TO NOVEL STAPLED PEPTIDE DUAL MDM4/2 INHIBITOR
Hematological Oncology2019-06-01
Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia
Blood2017-12-077 citations
Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of <i>WT p53</i> in patients with solid tumors and lymphomas.
Journal of Clinical Oncology2017-05-2078 citations